Guilford Pharmaceuticals, Inc.

Nova Pharmaceutical Corporation

Raymond J Patch

Gregory S Hamilton

Waclaw J Rzeszotarski

Maria E Guzewska

John W Ferkany

Ronald M Burch

John J Perumattam

Barry G Shearer

Suzanne R Ellenberger

Edward W Karbon, Jr

The present invention pertains to antagonists of excitatory amino acid neurotransmitter receptor antagonists, their method of preparation as well as compositions containing them which have the general formula: ##STR1## wherein n and m independently are 0, 1, 2, or 3; R.sub.1 is selected from the group consisting of hydrogen and R.sub.2 ; R.sub.2 is selected from the group consisting of hydrogen, halogen, halomethyl, nitro, amino, alkoxy, hydroxyl, hydroxymethyl, C.sub.1 to C.sub.6 lower alkyl, C.sub.7 to C.sub.12 higher alkyl, aryl and aralkyl, wherein if R.sub.2 is hydrogen, R.sub.1 is not hydrogen; R.sub.3 is selected from the group consisting of hydrogen and C.sub.1 to C.sub.6 lower alkyl; the stereoisomers thereof in their resolved or racemic form, and pharmaceutically acceptable salts thereof.

.omega.-[2-(phosphonoalkyl)phenyl]-2-aminoalkanoic acids as antagonists

PKC modulating compounds of the formula ##STR1## Also disclosed are pharmaceutical compositions including these compounds which inhibit PKC activity, methods of using these compounds to inhibit PKC activity in mammals, and intermediates useful in preparing the PKC modulating compounds.

Protein kinase C modulators

Growing community of inventors

Baltimore, MD, United States of America

Raymond J Patch